In the case of tarlatamab, the molecule binds to CD3 receptors on T cells and DLL3 on SCLC cells with the aim of stimulating the immune system to destroy the tumour. It’s a well-established ...

The bispecific T-cell engager targets DLL3 on tumor cells and CD3 on T cells, enhancing immune response against SCLC. The safety profile includes manageable cytokine release syndrome and ...

In the case of tarlatamab, the molecule binds to CD3 receptors on T-cells and DLL3 on SCLC cells, and it is the first drug in the anti-DLL3 class to be approved for marketing, as well as the first ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

In addition, the association of CD3 with the TCR–peptide–MHC complex transmits the activation signal to intracellular signalling molecules to initiate a signalling cascade in the T cell.

Title: ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer ZW209, a ...